Immunize.org has been refreshed! Take a tour.

Issue Number 48             January 21, 1999

CONTENTS OF THIS ISSUE

  1. Epivir-HBV (lamivudine) is approved by the FDA as oral treatment for chronic hepatitis B

----------------------------------------------------------

Back to Top

(1)
January 21, 1999
EPIVIR-HBV (LAMIVUDINE) IS APPROVED BY THE FDA AS ORAL TREATMENT FOR CHRONIC HEPATITIS B

On December 9, 1998, the FDA approved the first oral, anti-viral medication for the treatment of adults with chronic hepatitis B associated with evidence of hepatitis B viral replication and active liver inflammation. Epivir-HBV, a brand name for lamivudine, is available as a tablet and as an oral solution.

Epivir-HBV is manufactured by Glaxo Wellcome, Inc., based in Research Triangle Park, North Carolina.

For additional information about Epivir-HBV, read the package insert.

About IZ Express

IZ Express is supported in part by Grant No. 1NH23IP922654 from CDC’s National Center for Immunization and Respiratory Diseases. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.

IZ Express Disclaimer
ISSN 2771-8085

Editorial Information

  • Editor-in-Chief
    Kelly L. Moore, MD, MPH
  • Managing Editor
    John D. Grabenstein, RPh, PhD
  • Associate Editor
    Sharon G. Humiston, MD, MPH
  • Writer/Publication Coordinator
    Taryn Chapman, MS
    Courtnay Londo, MA
  • Style and Copy Editor
    Marian Deegan, JD
  • Web Edition Managers
    Arkady Shakhnovich
    Jermaine Royes
  • Contributing Writer
    Laurel H. Wood, MPA
  • Technical Reviewer
    Kayla Ohlde

This page was updated on .